Nasus Pharma (NSRX) Stock Price, News & Analysis

Company Overview

Nasus Pharma Ltd. is a specialty pharmaceutical company focused on developing intranasal powder-based medicines. Its proprietary platform is designed to deliver drug therapies through the nose, with the potential to support rapid administration without the need for injections or other conventional delivery methods.

The company’s development efforts are directed toward acute and emergency-care applications, including treatments for conditions in which rapid drug delivery may be important. Nasus Pharma has described its pipeline as including intranasal products intended for use in areas such as anaphylaxis, opioid overdose and other urgent medical situations.

Nasus Pharma is an early-stage company, and many of its product candidates remain under development and subject to clinical, regulatory and commercial milestones. Information about its broader commercial operations, geographic reach and leadership is limited.

Key Stats

• Today's Range: $2.89 to $3.02
• 50-Day Range: $2.82 to $3.92
• 52-Week Range: $1.98 to $9.50
• Volume: 4,784 shs
• Average Volume: 73,888 shs
• Market Capitalization: $34.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.50
• Consensus Rating: Buy

Nasus Pharma Stock Analysis - MarketRank™

Nasus Pharma scored higher than 74% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Nasus Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Nasus Pharma has a consensus price target of $12.50, representing about 333.3% upside from its current price of $2.89.

Amount of Analyst Coverage

Nasus Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nasus Pharma are expected to grow in the coming year, from ($0.84) to ($0.81) per share.

Price to Book Value per Share Ratio

Nasus Pharma has a P/B Ratio of 9.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.61% of the float of Nasus Pharma has been sold short.

Short Interest Ratio / Days to Cover

Nasus Pharma has a short interest ratio ("days to cover") of 3.65, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nasus Pharma has recently decreased by 11.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nasus Pharma does not currently pay a dividend.

Dividend Growth

Nasus Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Nasus Pharma has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

MarketBeat Follows

4 people have added Nasus Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nasus Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

Nasus Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/17/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSEAMERICAN:NSRX
• CIK: 2029039
• Web: www.nasuspharma.com
• Phone: 972-3573-6632
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nasus Pharma: $12.50
• High Price Target: $18.00
• Low Price Target: $7.00
• Potential Upside/Downside: +329.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.77
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 9.39

Miscellaneous

• Outstanding Shares: 11,710,000
• Free Float: N/A
• Market Cap: $34.08 million
• Optionable: N/A
• Beta: 4.25